ITRM फॉरेक्स के समाचार
Iterum Therapeutics Says FDA Determines To Take NDA For Sulopenem To Advisory Committee
Pharmaceutical company Iterum Therapeutics plc (ITRM) announced Friday that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women will be taken to Advisory Committee.
RTTNews
|
136 दिनों पहले
